Pharmaceutical multiple-units formulation

Details Pharmaceutical multiple-units formulation Pharmaceutical multiple-units formulation

1984-06-20

1986-08-19

Rose, Shep K.

Drug, bio-affecting and body treating compositions

Solid synthetic organic polymer as designated organic active...

Polymer from ethylenic monomers only

424 19, 424 32, 424 33, 424 35, A61K 922, A61K 924, A61K 928

Patent

active

046069097

ABSTRACT:
A pharmaceutical oral controlled release multiple-units formulation in which individual units comprise cross-sectionally substantially homogeneous cores containing particles of a sparingly soluble active substance, the cores being coated with a coating which is substantially resistant to gastric conditions, but which is erodable under the conditions prevailing in the small intestine, in particular an enteric coating which is substantially insoluble at a pH below 7 such as Eudragit.RTM. S (an anionic polymerizate of methacrylic acid and methacrylic acid methyl ester), is prepared by a process comprising comminuting an active substance together with a substance which is readily soluble in intestinal fluids such as an anionic detergent to obtain particles containing the active substance in intimate admixture with the readily soluble substance, combining the resulting particles into cross-sectionally substantially homogeneous cores together with components which accelerate the disintegration of the cores and intestinal fluids such as talc and saccharose, coating the individual cores with an erodable coating, and combining a multiplicity of the coated cores into a capsule or tablet formulation.
Such a coating may also be used when the active substance is a substance which exerts an irritating effect on the gastric mucosa and/or is unstable in an acidic environment.

REFERENCES:
patent: 3775537 (1973-11-01), Lehmann et al.
patent: 4083949 (1978-04-01), Benedikt
patent: 4173626 (1979-11-01), Dempski et al.
patent: 4193985 (1980-03-01), Bechgaard et al.
patent: 4291016 (1981-09-01), Nougaret
Yamanouchi, C.A., 94, #127362r (1981).
Hazler, C.A., 91, #181467e (1979).
Martin, C.A., 93, #245473e (1980).
Elgindy, C.A., 96:11599k (1982).
Lindberg, C.A., 77, #66167f (1972).
Porebski, C.A., 75, #25335z (1971).
Borzunov, C.A., 75, #121361a (1971).
Biosrame, C.A., 97, #44255u (1982).
Toyo, C.A., 97, #44326t (1982).
Bogentoft, C.A., 96, #57792n (1982).
Dreher, C.A., 94, #109115h (1981).
Biosrame, C.A., 91, #181383z (1979).
Lehmann, C.A., 91, #9441f (1979).
El-Sayed, C.A., 89, #204156v (1978).
Lehmann, C.A., 84, #95546d (1976).
Lehmann, C.A., 81, #111411b, #68497v, #964404f (1974).
Dittgen, C.A., 85, #198123p (1976).
Kach, C.A., 86, #60497c (1977).
Dittgen, C.A., 87, #11555g, (1977).
Dittgen C.A. 87 #189376n (1977).
Baggensen, S. et al (1981) Pharm. Acta Helv., 56, 85-92.
Bechgaard et al (1978) Drug Develop. Ind. Pharm. 4, 53-67.
Bechgaard et al (1978) J. Pharm. Pharmacol., 30, 690-692.
Bechgaard et al (1980) J. Pharma. Sci., 69, 1327-1330.
Bogentoft, et al (1978) Eur. J. Clin. Pharmacol., 14, 351-355.
Green, DM (1966) J. New Drugs, 6, 294-303.
McDonald et al (1977) J. Clin. Pharmacol., 17, 601-606.
Snedecor et al (1967) Iowa State University Press, Iowa, 271-275.

Affiliated with

Also associated with

Rating

Pharmaceutical multiple-units formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical multiple-units formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical multiple-units formulation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-393306